ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Session » (2039–2060) Pediatric Rheumatology – Clinical Poster III: Potpourri

Date: Tuesday, November 14, 2023

Time: 9:00AM-11:00AM

Meeting: ACR Convergence 2023

9:00AM-11:00AM
Abstract Number: 2055
A Randomized Controlled Trial of Two Hepatitis a Vaccine Doses Among Adolescents with Juvenile Idiopathic Arthritis and Crohn’s Disease on Immunosuppressive Therapy: A Pilot Study
9:00AM-11:00AM
Abstract Number: 2041
An Analysis of Recurrent Parotitis Patients Referred to Rheumatology Clinic
9:00AM-11:00AM
Abstract Number: 2039
Clinical, Immunologic, and Genetic Characteristics in Patients with Syndrome of Undifferentiated Recurrent Fevers (SURF)
9:00AM-11:00AM
Abstract Number: 2060
Creation of a Standardized and Collaborative Transfer Process from Pediatric to Adult Rheumatology
9:00AM-11:00AM
Abstract Number: 2048
Development and Usability Testing of Web-based Standardized Scoring Tool for Magnetic Resonance Images from Children with Chronic Nonbacterial Osteomyelitis (CNO)
9:00AM-11:00AM
Abstract Number: 2040
Distinguishing Multisystem Inflammatory Syndrome in Children from Typhus Using Artificial Intelligence: MISC vs. Endemic Typhus (AI-MET)
9:00AM-11:00AM
Abstract Number: 2058
IL-1 Blocking Treatment Slows the Progression of Sensorineural Hearing Loss in Patients with NOMID
9:00AM-11:00AM
Abstract Number: 2046
Implementation of an Automated Transition Readiness Assessment in a Pediatric Rheumatology Clinic
9:00AM-11:00AM
Abstract Number: 2042
Intraocular Cytokine Profiling of Autoimmune Uveitis
9:00AM-11:00AM
Abstract Number: 2059
Management of Iatrogenic, Recombinant Interleukin-1 Receptor Antagonist-type Amyloidosis on NOMID in Patients on Anakinra
9:00AM-11:00AM
Abstract Number: 2057
Medical Trauma and Its Association with Pain and Disability Risk in Children with Inflammatory Arthritis
9:00AM-11:00AM
Abstract Number: 2044
Monogenic Interferon Mediated Diseases: Novel Phenotype and Genotype Characteristics from Saudi Population
9:00AM-11:00AM
Abstract Number: 2056
Pediatric Acute-onset Neuropsychiatric Syndrome: Markers of Inflammation/autoimmunity at Clinical Presentation and Eventual Development of Arthritis and Other Autoimmune Diseases
9:00AM-11:00AM
Abstract Number: 2043
Phenotype of Musculoskeletal Manifestations in a Canadian Inception Cohort of Pediatric Patients with Inflammatory Bowel Disease
9:00AM-11:00AM
Abstract Number: 2053
Predictive Factors Associated with Treatment Response in Chronic Nonbacterial Osteomyelitis
9:00AM-11:00AM
Abstract Number: 2052
Risk Factors for Hospitalization for SARS-CoV-2 in Pediatric Patients with Rheumatic Diseases: A Systematic Review and Meta-analysis
9:00AM-11:00AM
Abstract Number: 2047
Safety of Baricitinib for COVID-19 Related Hyperinflammation in Pediatric Patients: A Large Tertiary Care Center Experience
9:00AM-11:00AM
Abstract Number: 2051
Screening Multisystem Inflammatory Syndrome in Children: Accuracy of SickKids Screening Pathway Compared to ACR Algorithm
9:00AM-11:00AM
Abstract Number: 2054
Superiority of Adalimumab in Treating Childhood Chronic Idiopathic Uveitis: Evidence from a Multicentre Experience
9:00AM-11:00AM
Abstract Number: 2045
Treatment Response in a Cohort of Pediatric Patients with Autosomal Dominant Neovascular Inflammatory Vitreoretinopathy (ADNIV)
9:00AM-11:00AM
Abstract Number: 2049
Vaccination Coverage and Caregiver Perspectives for Children with Rheumatic Diseases Compared to Healthy Controls
9:00AM-11:00AM
Abstract Number: 2050
Variability in Vaccination Practices in Children with Rheumatic Diseases: Results of a Rheumatology Provider Childhood Arthritis and Rheumatology Research Alliance (CARRA)-wide Survey

« View all sessions from this meeting

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology